neflamapimod

Phase 2Small molecule

EEIP Pharma Inc

neflamapimod is one of 108 small molecule programs targeting Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Huntington DiseaseActive, not recruiting

AphasiaActive, not recruiting

Primary Progressive AphasiaActive, not recruiting

Dementia With Lewy BodiesCompleted

Ischaemic StrokeActive, not recruiting

DementiaActive, not recruiting

StrokePhase 2

Active, not recruiting

Huntington DiseasePhase 2

Active, not recruiting

AphasiaPhase 2

Active, not recruiting

Primary Progressive AphasiaPhase 2

Active, not recruiting

Dementia With Lewy BodiesPhase 2

Completed

Ischaemic StrokePhase 2

Active, not recruiting

DementiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

neflamapimod

EEIP Pharma Inc

Phase 2

7 2

Zometa

Pfizer

Preclinical

1 3

Folvite

Eli Lilly

Preclinical

1 4

Proamatine

Repatha

Botox

RRevance Therapeutics, Inc.

Preclinical

2 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Haldol

DDePuy Orthopaedics

Preclinical

1 9

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Primary Progressive Aphasia

NCT07033481

Phase 2Active, not recruiting

Ischaemic Stroke

NCT06987643

Clinical

Trials by Indication[1]

Dementia2 trials

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Completed·EEIP Pharma Inc·Phase 2·NCT05869669·159 enrolled

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

Completed·EEIP Pharma Inc·Phase 2·NCT04001517·91 enrolled

Huntington disease1 trial

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

Terminated·EEIP Pharma Inc·Phase 2·NCT03980938·15 enrolled

Alzheimer's Disease1 trial

Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease

Completed·EEIP Pharma Inc·Phase 2·NCT03402659·161 enrolled

Ischaemic Stroke1 trial

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke

Active, not recruiting·EEIP Pharma Inc·Phase 2·NCT06987643·90 enrolled

Dementia With Lewy Bodies1 trial

An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies (DLB)

Completed·EEIP Pharma Inc·Phase 2·NCT06815965·26 enrolled

1 more indication

Primary Progressive Aphasia1 trial

A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)

Active, not recruiting·EEIP Pharma Inc·Phase 2·NCT07033481·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for neflamapimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — neflamapimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for neflamapimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EIP Pharma Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEIP Pharma Inc

neflamapimod

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Dementia2 trials

Huntington disease1 trial

Alzheimer's Disease1 trial

Ischaemic Stroke1 trial

Dementia With Lewy Bodies1 trial

Primary Progressive Aphasia1 trial

References

Drug Info

Quick Facts

Related News